SLC5A2 and chronic kidney disease: Moreover, several other novel drug classes appear to add further kidney benefit and albuminuria reduction specifically for patients with CKD and type 2 diabetes, also when they are treated with RAAS or SGLT2 inhibitors, such as glucagon-like peptide-1 (GLP-1) receptor agonists and the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone [35,36].